评价 WO2013116562A，一种用于治疗哮喘的口服活性 PI3Kδ 抑制剂。
Evaluation of WO2013116562A, an orally active PI3Kδ inhibitor for the treatment of asthma.
机构信息
Norman Consulting , 18 Pink Lane, Burnham, Bucks, SL1 8JW , UK
出版信息
Expert Opin Ther Pat. 2014 May;24(5):603-7. doi: 10.1517/13543776.2014.870155. Epub 2014 Jan 3.
PMID:24387136
Abstract
(S)-4-amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile is claimed as a highly selective, PI3Kδ inhibitor. It is claimed to be useful in the treatment of asthma and appears intended for oral administration. It is shown to be well absorbed after oral administration and to have reasonable metabolic stability.
摘要
(S)-4-氨基-6-((1-(5-氯-4-氧代-3-苯基-3,4-二氢喹唑啉-2-基)乙基)氨基)嘧啶-5-甲腈被宣称是一种高度选择性的 PI3Kδ 抑制剂。据称，它可用于治疗哮喘，且似乎拟用于口服给药。它经口服给药后显示出良好的吸收性，且具有合理的代谢稳定性。
Zotero 插件